Mouse monoclonal antibodies, raised against a synthetic antigen that mimics the MMP catalytic site, were shown to inhibit gelatinases via a TIMP-like binding mechanism, and to show therapeutic promise in a mouse model of inflammatory bowel disease [76]. The gene discussed is TIMP1; the disease is inflammatory bowel disease.